Abstract
Disease manifestations with Aspergillus spp. are very diverse and dependent on interaction between the fungus and the host. Invasive aspergillosis (IA) is the most severe form of Aspergillus - associated disease found in immunocompromised hosts. Infections are mainly due to Aspergillus (A.) fumigatus, an air-borne opportunistic pathogen that causes 90% of IA. Mortality rate of this disease is still very high (50-95%), partly because of diagnostic difficulties, limited antifungal treatment options, weak conditions of patients at risk; but also in part because understanding of virulence factors involved in A. fumigatus pathogenicity and interactions of the pathogen with the host immune system is still poor. This review focuses on properties of A. fumigatus in terms of putative virulence factors and interactions of the pathogen with a main focus on the innate immune system.
Keywords: Invasive aspergillosis, virulence, pathogenicity factors, classification of IA, innate immune response.
Current Pharmaceutical Design
Title:New Insights into Invasive Aspergillosis - from the Pathogen to the Disease
Volume: 19 Issue: 20
Author(s): Ulrike Binder and Cornelia Lass-Florl
Affiliation:
Keywords: Invasive aspergillosis, virulence, pathogenicity factors, classification of IA, innate immune response.
Abstract: Disease manifestations with Aspergillus spp. are very diverse and dependent on interaction between the fungus and the host. Invasive aspergillosis (IA) is the most severe form of Aspergillus - associated disease found in immunocompromised hosts. Infections are mainly due to Aspergillus (A.) fumigatus, an air-borne opportunistic pathogen that causes 90% of IA. Mortality rate of this disease is still very high (50-95%), partly because of diagnostic difficulties, limited antifungal treatment options, weak conditions of patients at risk; but also in part because understanding of virulence factors involved in A. fumigatus pathogenicity and interactions of the pathogen with the host immune system is still poor. This review focuses on properties of A. fumigatus in terms of putative virulence factors and interactions of the pathogen with a main focus on the innate immune system.
Export Options
About this article
Cite this article as:
Binder Ulrike and Lass-Florl Cornelia, New Insights into Invasive Aspergillosis - from the Pathogen to the Disease, Current Pharmaceutical Design 2013; 19 (20) . https://dx.doi.org/10.2174/13816128113199990366
DOI https://dx.doi.org/10.2174/13816128113199990366 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Poly (ADP-Ribosyl) Polymerase 1 Inhibitors: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery Interleukin-6/interleukin-6 Receptor Pathway as a New Therapy Target in Epithelial Ovarian Cancer
Current Pharmaceutical Design The Recent Progresses on The Improved Therapy of Melanoma by Novel Drug Delivery Systems
Current Drug Targets Diagnostic Methods in the Detection of Prostate Cancer: Prospective Observational Study
Current Medical Imaging A Proposed Screening Paradigm for Discovery of Covalent Inhibitor Drugs
Drug Metabolism Letters In Vivo Models of Childhood Leukemia for Preclinical Drug Testing
Current Drug Targets IAP Proteins Antagonist: An Introduction and Chemistry of Smac Mimetics under Clinical Development
Current Medicinal Chemistry The Effects of 5-Aza-2`-Deoxycytidine on DLC-1 Gene Expression, Methylation Level and Expression of Downstream Signaling Molecules Cdc42 in Multiple Myeloma
Current Signal Transduction Therapy The Use of Therapeutic Peptides to Target and to Kill Cancer Cells
Current Medicinal Chemistry Current Options in the Treatment of Mast Cell Mediator-Related Symptoms in Mastocytosis
Inflammation & Allergy - Drug Targets (Discontinued) Major Highlights of the CAR-TCR Summit, Boston, 2016
Anti-Cancer Agents in Medicinal Chemistry Molecular Genetics and Targeted Therapy in Hepatocellular Carcinoma
Current Cancer Drug Targets Immunotherapy in Bladder Cancer
Current Molecular Pharmacology Targeted Therapy Options for Treatment of Bone Metastases; Beyond Bisphosphonates
Current Pharmaceutical Design Potential Interactions between miRNAs and Hypoxia: A New Layer in Cancer Hypoxia
Anti-Cancer Agents in Medicinal Chemistry A Case of Ischemic Stroke in Acute Promyelocytic Leukemia at Initial Presentation: Relevance of All-Trans Retinoic Acid Treatment
Cardiovascular & Hematological Disorders-Drug Targets NF-κB Signaling Pathway Inhibitors as Anticancer Drug Candidates
Anti-Cancer Agents in Medicinal Chemistry Targeting Pathways Mediating Bone Disease
Current Pharmaceutical Biotechnology Emerging Roles for Modulation of microRNA Signatures in Cancer Chemoprevention
Current Cancer Drug Targets Therapeutic Immunoconjugates. Which Cytotoxic Payload: Chemotherapeutic Drug (ADC) or Radionuclide (ARC) ?
Current Cancer Therapy Reviews